Carlos Garcia-Padilla

Carlos Garcia-Padilla

Auto-generated profile, based on publicly available information

Carlos Garcia-Padilla

Department of Human Anatomy and Embryology, Faculty of Medicine, Institute of Molecular Pathology Biomarkers, University of Extremadura, 06006 Badajoz, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CGCarlos Garcia-Padilla
Carlos Garcia-Padilla
Estefanía Lozano VelascoEstefanía Lozano Velasco
Estefanía Lozano Velasco
MMMaría del Mar Muñoz-Gallardo
María del Mar Muñoz-Gallardo
JCJuan Manuel Castillo-Casas
Juan Manuel Castillo-Casas
SCSheila Caño-Carrillo
Sheila Caño-Carrillo
CLCarmen Lopez-Sanchez
Carmen Lopez-Sanchez
Various treatments based on drug administration and radiotherapy have been devoted to preventing, palliating, and defeating cancer, showing high efficiency against the progression of this disease. Recently, in this process, malignant cells have been found which are capable of triggering specific molecular mechanisms against current treatments, with negative consequences in the prognosis of the disease. It is therefore fundamental to understand the underlying mechanisms, including the genes—and their signaling pathway regulators—involved in the process, in order to fight tumor cells. Long non-coding RNAs, H19 in particular, have been revealed as powerful protective factors in various types of cancer. However, they have also evidenced their oncogenic role in multiple carcinomas, enhancing tumor cell proliferation, migration, and invasion. In this review, we analyze the role of lncRNA H19 impairing chemo and radiotherapy in tumorigenesis, including breast cancer, lung adenocarcinoma, glioma, and colorectal carcinoma.